Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | RORC | P51449 | 9/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CPT2 | P23786 | 1/20 | 0.53 |
| ▸ | CPT1A | P50416 | 1/20 | 0.53 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4562216 | 0.91 | RORC (0.57) | MAPTRORCPOLBCPT1ACPT1B | |
| SCHEMBL4540941 | 0.88 | RORC (0.53) | MAPTRORCPOLBTP53 | |
| SCHEMBL5023190 | 0.84 | RORC (0.73) | MAPTRORC | |
| SCHEMBL4561022 | 0.80 | RORC (0.51) | MAPTRORCCPT1ACPT1B | |
| SCHEMBL15610946 | 0.80 | RORC (0.59) | MAPTRORCCPT1ACPT1B | |
| SCHEMBL31456270 | 0.79 | MEN1 (0.62) | MAPTRORCPOLBTP53NLRP3 | |
| SCHEMBL5021838 | 0.79 | MAPT (0.70) | MAPTRORCPOLBTP53 | |
| SCHEMBL1495155 | 0.77 | MAPT (0.89) | MAPTPOLBTP53 | |
| SCHEMBL5021844 | 0.77 | RORC (0.68) | MAPTRORC | |
| SCHEMBL5023239 | 0.76 | MAPT (0.64) | MAPTPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638014-B1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF ROR-GAMMA ACTIVITY AND THE TREATMENT OF DISEASES | LYCERA CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9512111-B2 | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease | LYCERA CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME CORP. (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2012064744-A2 | TETRAHYDROQUINOLINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORϒ ACTIVITY AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088094-A1 | N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORC, RORB, RORA | MAPT 3512/4885RORC 1/4885POLB 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.